Ifat Geron
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ifat Geron has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Angela Maria Savino
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Edmond and Lily Safra Children's hospital Chaim Sheba Medical Center, Tel Hashomer, Israel
1 shared publication - Arndt Borkhardt
Department of Pediatric Oncology, Hematology and Clinical Immunology, Medical Faculty Heinrich Heine University Düsseldorf Düsseldorf Germany
1 shared publication - Arnon Nagler
Division of Hematology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
1 shared publication - Avigail Rein Gil
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Edmond and Lily Safra Children's hospital Chaim Sheba Medical Center, Tel Hashomer, Israel The Rina Zaizov Pediatric Hematology and Oncology Division Schneider Children's Medical Center
1 shared publication - Chela James
Department of Cancer Biology, UCL Cancer Institute, UCL, London, UK
1 shared publication - Hila Fishman
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Edmond and Lily Safra Children's hospital Chaim Sheba Medical Center, Tel Hashomer, Israel The Rina Zaizov Pediatric Hematology and Oncology Division Schneider Children's Medical Center
1 shared publication
Latest Publications
- Open Access
- 28 January 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
An instructive role for IL7RA in the development of human B-cell precursor leukemia
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is preceded by a clinically silent pre-leukemia. Experimental models that authentically re-capitulate disease initiation and progression in human cells are lacking. We previously described activating mutations in interleukin 7 receptor alpha (IL7RA) that are associated with the poor-prognosis Philadelphia-like (Ph-like) subtype of BCP-ALL. Whether IL7RA signaling has a role in initiation of human BCP-ALL is unknown.IL7RA is essential for mouse B-cell development; however, patients with truncatingIL7RAgermline mutations develop normal mature B-cell populations. Herein, we explore the consequences of aberrant IL7RA signaling activation in human hematopoietic progenitors on malignant B-cell development.Transplantation of human cord-blood hematopoietic progenitors transduced with activated mutant IL7RA into NOD/LtSz-scid IL2Rγnullmice resulted in B-cell differentiation arrest with aberrant expression of CD34+and persistence of pro-B cells that survive despite failing to achieve productive rearrangement of immunoglobulin V(D)J gene segments. Activation of IL7RA signaling enhanced self-renewal and facilitated the development of a BCP-ALL in secondary transplanted mice. The development of leukemia was associated with spontaneous acquired deletions in CDKN2A/B and IKZF1 similar to what is observed in Ph-like BCP-ALL in humans. Single cell gene expression analysis suggested that pre-leukemic cells resided within a subpopulation of early B-cell precursors with CD34+CD10highCD19lowimmunophenotype.The development of a bona fide BCP-ALL from IL7RA transduced cells supports the hypothesis that aberrant activation of the IL7RA pathway in human B-cell lineage progenitors has an instructive role by creating a pre-leukemic state which is vulnerable to transformation. These are the first demonstrations of a role for IL7RA in human B-cell differentiation and of a de-novo Ph-like BCP-ALL development from normal human hematopoietic progenitorsin vivo.
- 28 January 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
Open AccessAn instructive role for IL7RA in the development of human B-cell precursor leukemia
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is preceded by a clinically silent pre-leukemia. Experimental models that authentically re-capitulate disease initiation and progression in human cells are lacking. We previously described activating mutations in interleukin 7 receptor alpha (IL7RA) that are associated with the poor-prognosis Philadelphia-like (Ph-like) subtype of BCP-ALL. Whether IL7RA signaling has a role in initiation of human BCP-ALL is unknown.IL7RA is essential for mouse B-cell development; however, patients with truncatingIL7RAgermline mutations develop normal mature B-cell populations. Herein, we explore the consequences of aberrant IL7RA signaling activation in human hematopoietic progenitors on malignant B-cell development.Transplantation of human cord-blood hematopoietic progenitors transduced with activated mutant IL7RA into NOD/LtSz-scid IL2Rγnullmice resulted in B-cell differentiation arrest with aberrant expression of CD34+and persistence of pro-B cells that survive despite failing to achieve productive rearrangement of immunoglobulin V(D)J gene segments. Activation of IL7RA signaling enhanced self-renewal and facilitated the development of a BCP-ALL in secondary transplanted mice. The development of leukemia was associated with spontaneous acquired deletions in CDKN2A/B and IKZF1 similar to what is observed in Ph-like BCP-ALL in humans. Single cell gene expression analysis suggested that pre-leukemic cells resided within a subpopulation of early B-cell precursors with CD34+CD10highCD19lowimmunophenotype.The development of a bona fide BCP-ALL from IL7RA transduced cells supports the hypothesis that aberrant activation of the IL7RA pathway in human B-cell lineage progenitors has an instructive role by creating a pre-leukemic state which is vulnerable to transformation. These are the first demonstrations of a role for IL7RA in human B-cell differentiation and of a de-novo Ph-like BCP-ALL development from normal human hematopoietic progenitorsin vivo.